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Abstract
In breast cancer, circulating tumor cells (CTCs)/disseminated tumor
cells (DTCs) may serve as independent adverse prognostic
variables, to monitor the course of the disease and to predict
response or failure to cancer therapy. Most of the techniques to
enumerate DTCs in the bone marrow or CTCs in the bloodstream
of breast cancer patients rely on a combination of an enrichment
step and a detection step. A novel RT-PCR method, the AdnaTest
BreastCancer™ kit, was developed for the enrichment of CTCs from
peripheral blood of breast cancer patients followed by identification
of CTC-associated marker transcripts by reverse transcription and
PCR. Although this test has been demonstrated to identify breast
cancer patients at risk, standardization of this technique and direct
comparison with other established breast cancer CTC enrichment
and detection techniques is still lacking, but highly needed. This is
done best within prospective clinical trials, such as in the ongoing
DETECT, SUCCESS, and BR-01-2004 trials.
In the previous issue of Breast Cancer Research, Fehm and
colleagues evaluated the correlation between circulating
tumor cells (CTCs) and disseminated tumor cells (DTCs) in
the bone marrow of patients afflicted with primary breast
cancer [1]. For this, the authors investigated blood samples
from 431 patients for the presence of CTCs by assessing
mRNA expression of epithelial cell-associated transcripts
EpCAM, MUC1, and HER2, employing the novel AdnaTest
BreastCancer™ kit (AdnaGen AG, Langenhagen, Germany).
The mRNA expression of receptors for the steroid hormones
estrogen and progesterone was determined via accompany-
ing in-house RT-PCR tests.
The DTC status was examined in the bone marrow of 414
patients by immunocytochemistry, using the pan-cytokeratin
antibody A45-B/B3. CTCs were detected in 13% of the
patients and DTCs were detectable in 24% of the patients
[1]. The presence of DTCs in the bone marrow only weakly
correlated with the presence of CTCs in the blood. CTCs
were mostly found in triple-negative tumors (negative for
estrogen receptor, for progesterone receptor, and for HER2
expression), and CTCs in general were mostly found to be
triple-negative, regardless of the estrogen receptor status,
progesterone receptor status and HER2 status of the primary
tumor tissue.
Based on these data, one may speculate that the tumor
biological features of CTCs and DTCs are quite different –
but, without validation in other breast cancer collectives, one
should act with caution when using this information for the
clinical management of breast cancer patients subject to
adjuvant therapy.
Although potentially interesting, we would like to emphasize
that the data presented by Fehm and colleagues [1] have to
be discussed in the framework of the 2007 update of recom-
mendations for the use of cancer biomarker tests, published
by the American Society of Clinical Oncology regarding
prevention, screening, treatment, and surveillance of breast
cancer [2]. The Update Committee came to the conclusion
that data available at that point were insufficient to recom-
mend adjuvant therapy to a particular patient, if based only on
the presence of bone marrow DTCs.
Because bone marrow may be a reservoir of latent
micrometastatic cells [3], in the future the detection of DTCs
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in the bone marrow may become more important in the
context of therapies such as bisphosphonates interfering with
bone marrow–tumor cell interactions [4]. Although the
measurement of CTCs in blood to influence treatment
decisions is not yet ready for routine use, the 2009 St Gallen
recommendations [5] recognized the potential of new
technological advances to phenotypically characterize
individual CTCs and the identification of therapeutic targets
such as HER2. However, until additional validation would
confirm the clinical value of existing test formats, and before
CTC/DTC testing could achieve standard-of-care status,
improvement in the sensitivity, precision, and reproducibility
of the detection methods has to be provided, preferentially by
multicentric prospective clinical trials.
Two different methods to screen bone marrow aspirates of
breast cancer patients for DTCs are in use – namely,
antibody-based cytologic/cytometric approaches and molecular
approaches [6]. Most frequently, antibodies against certain
epithelium-specific antigens such as cytoskeleton-associated
cytokeratins, surface adhesion molecules, or growth factor
receptors are applied for the detection of carcinoma cells [7].
As an alternative testing method, real-time RT-PCR-based
protocols for DTC detection in the bone marrow of breast
cancer patients have become available [8].
Similar to the enrichment and detection methods for DTCs,
most of the techniques employed to detect and characterize
CTCs rely on a combination of an ex vivo enrichment step by
adding ferrofluids loaded with antibodies directed towards
epithelial cell surface epitopes, such as EpCAM, and a
detection step, utilizing a few milliliters of anticoagulated
blood. For this, the USA Food and Drug Administration-
approved immunobead-based CellSearch CTC detection
system is widely used [9], but alternative bead-based or chip-
based sampling techniques are also in use [10-12].
The AdnaTest BreastCancerSelect/AdnaTest BreastCancer-
Detect kit (AdnaGen AG) used by Fehm and colleagues was
developed for the enrichment of CTCs from peripheral blood
of breast cancer patients, followed by detection of breast
cancer-associated gene expression in immunomagnetically
enriched tumor cells by reverse transcription and PCR [1].
The test is considered positive if a PCR fragment of at least
one of the tumor-associated transcripts for EpCAM, for
MUC1, or for HER2 is clearly detected. In spite of this, these
transcripts can also be identified by sensitive RT-PCR assays
in normal blood or tissues, and therefore clear cutoff values
need to be defined and validated [10].
Unfortunately, the data of large-scale DTC/CTC validation
studies, also addressing standardization and comparison of
various DTD/CTC sampling and detection technologies, have
not yet been reported. Recent meeting reports, however,
disclosed concordance rates for data obtained with the
CellSearch™ test system (Veridex LLC, Raritan, NJ, USA) and
with the AdnaTest BreastCancer™ kit of 68% and 88%
[1,13,14]. A performance evaluation breast cancer study
(BR-01-2004) to demonstrate this advantage of the
AdnaTest BreastCancer™ kit as a new tool for decision
guidance in cancer therapy over standard CTC detection
methods is ongoing. A prospective German multicenter trial
(DETECT) in metastatic breast cancer using both methods
has also recently completed its recruitment, but data have not
yet been published [1]. The same position is true for the
SUCCESS trial, a German prospective multicenter breast
cancer trial employing the CellSearch technique, to assess
the value of CTCs in the adjuvant setting [15].
CTC/DTC testing seems to have significant future potential
value in the identification of breast cancer patients at risk for
disease recurrence, for stratification of patients to adjuvant
therapies, and for therapy response monitoring [4,5]. None-
theless, optimization and standardization of DTC/CTC
detection techniques is highly needed, preferentially within
prospective randomized clinical trials.
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